Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Influenza, Human: full-pipeline trial registry

3 of 19 indexed Influenza, Human trials are currently recruiting.

Corpus placement: #902 of 28,707 conditions by registered trial count.

19 US clinical trials · 3 currently recruiting · #902 of 28,707 conditions by registered trial count

Influenza, Human: 19 US clinical trials tracked, 3 recruiting.

Influenza, Human is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 5 of these trials.

Enrollment posture brief

Registry condition influenza-human

OPEN 3 | RECR 16% | LATE 8 | EARLY 6 | RANK #902 | SPON 5

Nearest open-share peer: Bacterial Infections (16% recruiting · 19 trials)

Amyotrophic Lateral Sclerosi52.6%Anesthesia, Local42.1%Alcohol Consumption36.8%Attention Deficit Hyperactiv26.3%Influenza, Human (this)16%
Open-enrollment share among volume-matched conditions near Influenza, Human

Influenza, Human lists 3 open slots (16% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Influenza, Human on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Influenza, Human is recruiting below its size-band peers.

    3 of 19 indexed trials (15.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Influenza, Human research.

    GlaxoSmithKline accounts for 5 of 19 trials (26.3%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Influenza, Human enrolment sits around 626 participants.

    Median target enrolment is 626 among the 19 trials that report a genuine target (sentinel values excluded). 5 of those (26.3%) plan for fewer than 100 participants.

  4. Influenza, Human research is mostly interventional.

    16 interventional and 3 observational studies make up this index (84.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 35Phase 43

Open and recent trials

19 total, page 1 of 1

RECRUITING Phase 2 960 participants

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

GlaxoSmithKline

NCT07204964

RECRUITING Phase 4 700 participants

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

University of Pennsylvania

NCT05108818

RECRUITING 50 participants

Flu Infection at UPHS

University of Pennsylvania

NCT06807840

ACTIVE NOT RECRUITING Phase 3 35,800 participants

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Seqirus

NCT06087640

ACTIVE NOT RECRUITING Phase 2 776 participants

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

GlaxoSmithKline

NCT07121192

COMPLETED NA 228,000 participants

Mail Outreach To Increase Vaccination Acceptance Through Engagement

Brigham and Women's Hospital

NCT02243774

COMPLETED 18,157 participants

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

Evidation Health

NCT06207929

COMPLETED Phase 3 2,250 participants

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Seqirus

NCT02914275

COMPLETED Phase 3 2,044 participants

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Seqirus

NCT05044195

COMPLETED Phase 2 1,019 participants

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

BioNTech SE

NCT05596734

COMPLETED Phase 3 626 participants

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

GlaxoSmithKline

NCT01231620

COMPLETED Phase 4 465 participants

Immunologic Response to FluMist vs. Flucelvax

Richard Zimmerman MD

NCT03982069

COMPLETED Phase 1 440 participants

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Pfizer

NCT05227001

COMPLETED Phase 4 402 participants

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Seqirus

NCT02212106

COMPLETED Phase 3 228 participants

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Hoffmann-La Roche

NCT00545532

COMPLETED Phase 1 40 participants

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

GlaxoSmithKline

NCT01353729

COMPLETED NA 29 participants

Resistance Exercise to Improve Flu Vaccine for Older Adults

University of Houston

NCT03736759

COMPLETED Phase 1 28 participants

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

GlaxoSmithKline

NCT01258530

COMPLETED 10 participants

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

Vanderbilt University Medical Center

NCT03743688

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 5
Phase 4 3

Top Sponsors

Named interventions

Most-linked intervention names on Influenza, Human records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

oseltamivir Drug
2 trials
Comparator 2 Combination
2 trials
Comparator 1 Combination
2 trials
Core letter signed by SG + enhanced implementation prompt Behavioral
1 trials
Core letter signed by Surgeon General + implementation prompt Behavioral
1 trials
Core letter signed by the Director of the National Vaccine Program Behavioral
1 trials
Core letter signed by Surgeon General Behavioral
1 trials
Comparator QIV Biological
1 trials

US sites by state

Facility locations filed on Influenza, Human trials. A trial with sites in several states counts in each.

California 10 trials
Florida 8 trials
Alabama 8 trials
Texas 5 trials
New York 5 trials
Georgia 5 trials
Arizona 5 trials
South Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Influenza, Human page

19 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Influenza, Human trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • GlaxoSmithKline sponsors the most Influenza, Human trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Influenza, Human condition card totals 19 registered trials; most-linked intervention oseltamivir; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.